CVS Health on Wednesday blew past first-quarter earnings and revenue estimates and raised its 2026 guidance as its insurance business improved, with the company saying all of its business segments — insurer Aetna, its retail pharmacy and health services unit — surpassed Wall Street's expectations. The numbers are being celebrated at the top, while the machinery underneath keeps grinding: CVS said medical costs are still too high and that it has internal programs to "take cost out of the way we do work."
Who Benefits From the Upside
CVS now expects full-year profit of between $7.30 and $7.50 per share, up from previous guidance of $7 to $7.20 per share. It also expects revenue of at least $405 billion in 2026, up from a prior outlook of at least $400 billion. CVS CFO Brian Newman said the majority of the $5 billion increase was "reflective of the tail winds we're seeing" for insurer Aetna.
That is the language of a giant health-care apparatus translating pressure into profit. The company posted net income of $2.94 billion, or $2.30 per share, for the first quarter, compared with net income of $1.78 billion, or $1.41 per share, in the same period a year earlier. Excluding certain items, adjusted earnings were $2.57 per share, above the $2.20 expected by analysts surveyed by LSEG. Revenue was $100.43 billion, compared with the $95.09 billion expected by analysts and up 6.2% from a year earlier.
Shares of CVS rose more than 7% on Wednesday.
The Cost-Cutting Machine
The insurance business brought in $35.97 billion in revenue during the quarter, up around 3% from the first quarter of 2025 and above the $33.28 billion expected by analysts. Newman said Aetna's performance reflected underlying strength and organizational changes to processes or technology that have enabled the company to "do things more efficiently."
The insurance segment's medical benefit ratio fell to 84.6% from 87.3% a year earlier, compared with analysts' expectation of 86.3%. That drop is the kind of metric investors love and patients never see in the same light: a lower ratio means more of the money stays inside the corporate structure instead of going out in care.
Newman said medical costs are still too high, but CVS has internal programs to "take cost out of the way we do work" and can better forecast medical cost trends, saying he is happy "we're not getting a lot of surprises." He said CVS now needs to focus on using the same tools to reduce medical costs.
CVS said the year-over-year improvement in the unit was also due to the lack of a premium deficiency reserve, which had been recorded in the same period in 2025. The company’s own accounting changes and process changes are part of the same corporate discipline: squeeze harder, predict better, and keep the surprises away from the balance sheet.
What the Segments Deliver
The pharmacy and consumer wellness division posted $31.99 billion in sales, relatively flat from a year earlier and above the $31.70 billion expected by analysts. The unit dispenses prescriptions in CVS' more than 9,000 retail pharmacies and provides services such as vaccinations and diagnostic testing.
The health services segment generated $48.24 billion in revenue, up 11% from a year earlier. That unit includes the pharmacy benefits manager Caremark, which negotiates drug discounts with manufacturers on behalf of insurance plans, creates formularies and reimburses pharmacies for prescriptions. In other words, the same corporate structure that sells the medicine also helps decide how the medicine is priced, routed, and paid for.
Newman said, "From an investor lens, we said let's put out realistic, reasonable targets and then find pathways to outperform. And we did that throughout at the end of last year and the quarter." He added, "So to beat and raise, which I think is probably the fourth or fifth consecutive, it feels like we're delivering on that." He also said, "So confident in the year, but still taking a cautious or prudent view," noting that medical costs are still too high.
The whole performance is presented as discipline and efficiency, but the facts show a familiar hierarchy: Wall Street gets the beat-and-raise, Aetna gets the tail winds, and the people moving through 9,000 pharmacies and insurance networks are left inside a system built to "take cost out" and call it progress.